as 11-25-2025 3:02pm EST
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 93.9M | IPO Year: | 2021 |
| Target Price: | $8.33 | AVG Volume (30 days): | 591.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $3.28 | Next Earning Date: | 11-12-2025 |
| Revenue: | $762,000 | Revenue Growth: | -96.99% |
| Revenue Growth (this year): | -99.94% | Revenue Growth (next year): | 453067.90% |
CNTB Breaking Stock News: Dive into CNTB Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
ACCESS Newswire
12 days ago
GlobeNewswire
14 days ago
Simply Wall St.
21 days ago
ACCESS Newswire
a month ago
Simply Wall St.
2 months ago
Simply Wall St.
5 months ago
GlobeNewswire
5 months ago
The information presented on this page, "CNTB Connect Biopharma Holdings Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.